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A B S T R A C T
Sleep disordered breathing is a rather common problem in the general population. 
Apnea during sleep can be divided into three types: central, obstructive and mixed. 
In central apneas there is lack of both airflow and respiratory efforts. It is recognized 
by its waxing-waning pattern of respiration called Cheyne-Stokes respiration. Central 
sleep apnea is most commonly seen in patients with heart failure and its prevalence 
among this group of patients is estimated to be as high as 30-40%. Obstructive sleep 
apnea occurs approximately in 5-15% of the general population. It usually affects 
middle-aged men with an increased body-mass index and a large neck circumference. 
It is characterized by repetitive complete or partial obstruction of the upper airway 
during sleep, which is followed by increasing and ineffective respiratory efforts.
Sleep fragmentation in patients with sleep apnea-hypopnea syndrome results in sle-
epiness, fatigue, morning headaches and depression. This daytime presentation to-
gether with loud snoring, choking and pauses of respiration during sleep should make 
primary care physicians suspicious of sleep disordered breathing. The best method 
used for the diagnosis of sleep apnea syndrome is overnight polysomnography. The 
pathophysiologic mechanisms, which take place in sleep apnea, include sympathetic 
activation, hypercoagulability, inflammation and production of pro-inflammatory 
cytokines, endothelial dysfunction, oxidative stress and metabolic dysfunction. All 
these mechanisms are associated with the development and progression of cardiovas-
cular disease. There is a strong linkage between sleep apnea and hypertension, sys-
tolic and diastolic dysfunction of the left ventricle, congestive heart failure, coronary 
artery disease, cardiac arrhythmias, stroke and pulmonary disease.
Given the increased morbidity and mortality of patients with sleep apnea, an effective 
treatment must be started as soon as possible after the diagnosis is made. Currently, 
nasal continuous positive airway pressure constitutes first line therapy. This therapy 
improves both quality of sleep and cardiovascular and general outcomes.
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i N T R o d U C T i o N
Apnea in adults is defined as the cessation of airflow 
(>90% reduction in tidal volume) for ≥10 s. Hypopnea is 
characterized by a decrease but not complete cessation of 
airflow by 30-50% of normal (reduction in tidal volume of 50-
90%) usually in association with a reduction in oxyhemoglobin 
saturation by at least 3% - 4%. These breathing disorders are 
commonly encountered during sleep and have been strongly 
associated with the pathogenesis and progression of cardio-
vascular disease (CVD).1
The American Academy of Sleep Medicine formulated 
the definition for Sleep Apnea Hypopnea Syndrome (SAHS), 
also referred as Sleep-Disordered Breathing Disorders, which 
is limited during sleep and is characterized by the following 
diagnostic criteria: either excessive daytime sleepiness not ex-
plained by other factors or a variety of symptoms, such as chok-
ing, gasping during sleep, recurrent awakenings from sleep, 
unrefreshing sleep, daytime fatigue, impaired concentration, 
accompanied by overnight polysomnography demonstrating 
≥5 obstructive breathing events per hour during sleep.2 Sleep 
apnea can be divided into 3 types: central, obstructive and 
mixed. Central sleep apnea (CSA) is defined as a situation in 
which there is absence of both respiratory efforts and airflow. 
Obstructive sleep apnea (OSA), on the other hand, is a con-
dition described as repetitive complete or partial obstruction 
of the upper airway during sleep, characterized by increasing 
and ineffective respiratory efforts. Finally, mixed sleep apnea 
is the combination of the previous two disorders.
e P i d e M i o L o G y 
Charles Dickens -the novelist- was the first to describe a 
sufferer from OSA named Joe, in his novel “The Posthumous 
Papers of the Pickwick Club”, published in 1836. Joe was an 
obese boy, who snored loudly and was excessively sleepy. 
Broadbent in 1877 was the first physician who described the 
clinical features of OSA.3 The first international symposium of 
hypersomnia with periodic breathing was organized in Italy in 
1972 from Lugarasi and Sadoul. Guilleminault et al4 reported 
the occurrence of this syndrome in nonobese patients and chil-
dren; the term ‘Pickwickian syndrome’ (extreme obesity and 
excessive sleepiness) is outdated and has been supplanted by 
‘obesity-hypoventilation syndrome’ which is characterized by 
chronic hypoventilation and hypercapnia during wakefulness.5
The prevalence of OSA varies in adults from 1% to 5% 
in men and 1.2% to 2.5% in women between the ages of 30 
and 60 years. Young et al6 estimated that among middle-aged 
adults, 93% of women and 82% of men with OSA have been 
underdiagnosed. Sleep apnea is more frequent among older 
people and its effects can be more severe than in younger 
people because there is a physiological decline in sleep quality 
with age. Its prevalence in the elderly (age >65 years) has been 
reported to be as high as 62%.7 The variability in the incidence 
of OSA is due to differences in the population studied in vari-
ous trials regarding age, body mass index and genetic factors, as 
well as differences in monitoring sleep and the criteria used to 
define an apneic or hypopneic event.8 Parish et al9 estimate that 
the occurrence of OSA ranges from 5% to 15% in the general 
population while women after menopause develop OSA at a 
rate similar to men.10 During the last few decades pediatric 
OSA has been recognized as a cause of significant morbidity 
among children and its prevalence diagnosed by varying criteria 
ranges widely from 0.1 to 13%, although most studies report 
a figure between 1 and 4%.11 Central sleep apnea is less com-
mon than OSA in the general population as it concerns <10% 
of the patients with sleep disordered breathing reported at 
most sleep laboratories.12 Obstructive sleep apnea correlates 
with obesity and CVD, especially hypertension, while CSA is 
frequent in patients with heart failure. 
The severity of SAHS is determined by the apnea-
hypopnea index (AHI), which is the number of apneic and 
hypopneic events per hour of sleep. Using the AHI we can 
divide sleep apnea syndrome into 3 levels of severity: mild 
(AHI = 5-14 events per hour), moderate (AHI = 15-29 events 
per hour) and severe (AHI ≥30 events per hour). An AHI <5 
is considered normal and patients with very severe OSA may 
have an AHI exceeding 100. Most of the studies have shown 
that ≈1 in 5 adults has at least mild OSA and 1 in 15 has mod-
erate or severe OSA. It is estimated that >85% of patients 
with clinically significant and treatable OSA have never been 
diagnosed and referral populations of OSA patients represent 
only the ‘tip of the iceberg’ of OSA prevalence.1 The “Wis-
consin Sleep Cohort study” reported that SAHS is associated 
with lower general health status before and after adjustment 
for age, sex, body mass index, smoking status, alcohol usage 
or history of cardiovascular conditions.13 Four major studies 
of OSA showed that the prevalence of severe OSA is 7% to 
14% in men and 2% to 7% in women, while the prevalence of 
mild OSA is 17% to 26% in men and 9% to 28% in women.14
P A T H o P H y S i o L o G y  o F  S L e e P 
d i S o R d e R e d  B R e A T H i N G
Obstructive sleep apnea is characterized by periodic col-
lapse of the upper airway during sleep leading to obstruction. 
The site of upper airway obstruction lies in the pharynx, 
velopharynx, oropharynx and hypopharynx. The pharyngeal 
luminal area depends on two opposite forces: the intrapha-
ryngeal negative suction pressure and the dilating forces of the 
pharyngeal muscles. The pharyngeal muscles are activated by 
the central nervous system in order to maintain the pharyn-
geal patency in healthy awake individuals. The activation is 
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normally reduced during sleep. The reduced neural activation, 
combined with anatomical abnormalities of the pharynx, for 
example excess posterior pharyngeal tissue, an enlarged tongue 
or a low-hanging palate, leads to repetitive hypopneic or apneic 
episodes during sleep in patients with OSA. Pharyngeal muscle 
activation is also impaired by alcohol, sleep deprivation, an-
esthesia and sedative hypnotics. Another mechanism of OSA 
is nasal obstruction frequently observed in allergic rhinitis, 
hypertrophic tonsils and bony structural defects.
The total occlusion or the narrowing of the upper airway 
reduces ventilation and gas exchange in the alveolar membrane 
of the lung tissue, resulting in hypoxia and hypercapnia. As the 
oxygen saturation decreases and the levels of PaCO2 increase, 
chemoreceptors in the carotids, the aorta and the brain stem 
are activated. Respiratory effort increases in response to these 
stimuli and provokes repeated arousals during the night, frag-
menting sleep. The arousal from sleep leads to a surge of the 
dilator muscles of the pharynx and resolves the obstruction. 
Hypoxia and hypercapnia are the major stimuli for sympathetic 
hyperactivity and the cyclical changes in vagal tone. The im-
balance of the autonomous nervous system during sleep is the 
key mechanism for the association of sleep apnea with CVD. 
The sympathetic surge occurring at the end of the apneic 
event leads to vasoconstriction and increases of peripheral 
vascular resistance in the systemic and pulmonary circulation. 
Moreover, there is an increase in circulating catecholamines 
and sympathetic activity during the day in patients with OSA 
compared with healthy controls.15,16
Central sleep apnea and Cheyne-Stokes respiration, a dis-
order most commonly seen in patients with heart failure, can 
be defined as a form of periodic breathing in which apneas and 
hypopneas alternate with ventilatory periods having a waxing 
and waning pattern of tidal volume. Cheyne-Stokes respira-
tion generally occurs in patients with congestive heart failure 
(CHF) because of hyperventilation and increased carbon 
dioxide chemosensitivity. The key mechanism is fluctuation 
of PaCO2 below and above the apneic threshold.17 Patients 
with congestive heart failure and CSA have lower PaCO2 
both during wakefulness and sleep, than those without CSA. 
In a study by Sin et al,18 the major risk factor for CSA was 
hypocapnia during wakefulness (PaCO2 <38 mmHg; odds 
ratio 4.33). Other risk factors for CSA were male gender (odds 
ratio 3.5), atrial fibrillation (odds ratio 4.13) and age >60 years 
(odds ratio 2.37).
In patients with CHF, left ventricular filling pressure is 
increased. Pulmonary congestion provokes hyperventilation 
through stimulation of pulmonary vagal irritant receptors. This 
phenomenon results in hypocapnia. When PaCO2 falls below 
the apnea threshold an episode of central apnea is triggered. 
During apnea, hypoxemia and hypercapnia occur, initiating 
breathing and sometimes leading to arousal. Hyperventilation 
following arousals leads to a decrease in PaCO2, thus a new 
episode of apnea is triggered (Fig. 1). This cycle is repeated 
through the night.
Unlike OSA, arousals in CSA occur after the onset of venti-
lation. An arousal in OSA represents a defense mechanism that 
relieves obstruction and terminates apnea. On the contrary, 
the resumption of airflow in CSA is not always dependent 
on arousal. Arousals actually trigger and propagate central 
apneas as mentioned already. Cheyne-Stokes respiration-
CSA appears predominantly during non-rapid eye movement 
(nREM) sleep, while OSA is more common during rapid eye 
movement (REM) sleep. During REM phase arousability 
to respiratory stimuli, ventilatory surge and hypocapnia are 
reduced compared with the lighter stages of nREM sleep.
Another mechanism for hypocapnia resulting in CSA 
in heart failure is increased carbon dioxide chemoreceptor 
responsiveness. Increases in sensitivity of chemoreceptors 
increase the tendency to hyperventilate and reset the prevail-
ing PaCO2 closer to the sleeping apneic threshold. Under this 
condition, even a modest increase in ventilation can drive 
PaCO2 below the apneic threshold and trigger a central apnea. 
Lorenzi et al19 studied the effect of inhaled CO2 on CSA, in 
patients with heart failure and came to the conclusion that 
a rise of PaCO2 by just 1-3 mmHg was enough to eliminate 
central apneas and hypopneas. CO2 inhalation has the same 
impact on idiopathic CSA. Prolonged circulation time due to 
diminished cardiac output in heart failure causes a delay in 
transmitting changes in arterial blood gas within the lung tis-
sue to peripheral chemoreceptors. This could destabilize the 
respiratory control system by means of influencing periodic 
breathing cycle length.
Cheyne-Stokes respiration provokes rises in heart rate and 
blood pressure similar to OSA, and the responsible mechanism 
is again an increase in sympathetic nervous activity. Severe 
CSA is associated with impaired cardiac autonomic control 
and increased cardiac arrhythmias. Central sleep apnea is 
also highly prevalent in patients without overt heart failure 
FiGURe 1. Sleep fragmentation due to central sleep apnea in 
patients with heart failure.
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but with asymptomatic left ventricular dysfunction. Fifty-five 
per cent of 47 patients with left ventricular ejection fraction 
≤40% studied by Lanfranchi and colleagues20 had CSA with 
an AHI ≥15 and the severity of CSA was not related to the 
severity of hemodynamic impairment measured by exercise 
tolerance and echocardiographic indices. In the same study the 
prevalence and severity of CSA were higher in patients with 
ischemic cardiomyopathy than in patients with nonischemic 
cardiomyopathy (P <0.05). 
Continuous positive airway pressure (CPAP) treatment of 
both obstructive and central apneas in patients with heart fail-
ure improves ejection fraction, functional class and transplant-
free survival. Treatment with CPAP in OSA resolves obstruc-
tion and decreases mean intrathoracic pressure. In addition, 
it eliminates post-apneic surges of sympathetic activation and 
rises of blood pressure, resulting in a reduction of cardiac af-
terload. Through these mechanisms CPAP treatment improves 
cardiac function. Treatment of OSA with CPAP reduces atrial 
natriuretic peptide (ANP), while levels of brain natriuretic 
peptide (BNP) are not associated with OSA in patients with 
or without coexisting heart failure.21 Supplemental O2 reduces 
the severity of CSA by suppressing respiratory drive and raising 
PaCO2 above the apnea threshold.
C L i N i C A L  P R e S e N T A T i o N  A N d 
d i A G N o S i S  o F  S L e e P  d i S o R d e R e d 
B R e A T H i N G
The clinical features that should make primary care phy-
sicians suspicious of SAHS are daytime sleepiness, morning 
headaches, choking, loud snoring and pauses of inspiration 
reported by sleep partners. Other common symptoms are 
personality changes, depression, irritability, aggressiveness, 
decreased libido, sexual dysfunction and even impotence.22 
These symptoms are attributed to fragmentation of sleep 
and frequent arousals and correlate with the severity of OSA. 
Nocturnal symptoms are more specific than daytime symptoms. 
Seventy five percent of patients experience apneic episodes 
terminated by gasps, choking sounds, snorts, vocalizations and 
brief arousals. Loud snoring followed by periods of silence is a 
usual symptom. About 50% of patients have diaphoresis and 
restlessness. Other nocturnal symptoms include dryness of 
mouth in 74% of patients, nocturia in 28%, esophageal reflux, 
drooling in 36% and dyspnea. 
In OSA patients, physical examination usually reveals ana-
tomic obstruction of the upper airway due to septal deviation, 
adenotonsillar hypertrophy, retrognathia, dental malocclusion, 
narrow maxillas and mandible. Obesity and body mass index 
>30 kg/m2, neck circumference >40 cm, male gender or 
postmenopausal status in women and positive family history 
of OSA make the diagnosis of sleep apnea more probable.23 
Other risk factors for OSA are race, age >40, alcohol ingestion 
before bedtime, underlying hypertension, metabolic syndrome, 
Down syndrome and Marfan disease (Table 1).
In order to appropriately evaluate a patient with suspected 
SAHS, a detailed history and physical examination is needed. 
However, the predictive value of clinical features in diagnos-
ing OSA had a sensitivity of 60% and a specificity of 63% in a 
report by Hoffstein and Szali.24 Various scales have been used 
to evaluate daytime sleepiness. Among them, the “Stanford 
Sleepiness Scale” and the “Epworth Sleepiness Scale” are most 
commonly used to measure the severity of the condition.25,26 
The major challenge for the clinician is the differential diagno-
sis between benign snoring and snoring related to apnea. The 
gold standard for the diagnosis is overnight polysomnography. 
This includes electroencephalographic, electrooculographic, 
electromyographic, oxygen saturation, oral and nasal airflow, 
respiratory effort, electrocardiographic and leg movement 
recordings. Although home studies have been used, equipped 
with portable devices, in order to measure oxygen saturation, 
heart rate, respiratory effort and airflow, they have had a lower 
efficacy for the diagnosis compared with full night polysom-
nography. Overnight oximetry alone measures only nocturnal 
desaturation and does not provide information about sleep 
architecture. Split night-full night polysomnography may be 
considered as an option for the diagnosis. In this case the first 
half of the night is spent in diagnostic recording and the other 
half is used to titrate CPAP, the most popular therapy cur-
rently used for OSA. This method allows a quicker diagnosis 
at reduced expense in some cases. 
Considering the expense required for the diagnosis, one 
could wonder why it is so important to distinguish patients with 
sleep disordered breathing. The answer to this question arises 
from a large number of population studies connecting sleep 
disordered breathing with CVD and higher mortality. He et 
al27 reported that about 40% of patients with severe OSA died 
during a follow- up period of 8 years. Partinen et al28 observed 
TABLe 1. Risk Factors for Obstructive Sleep Apnea (OSA)
Body mass index (BMI) >30 kg/m2 
Neck circumference >40 cm 
Male gender or postmenopausal status in women 
Positive family history of OSA 
Race 
Age >40 years







a higher risk of death due to vascular disease in patients with 
untreated OSA. Sleep disordered breathing has been shown 
to be associated with increased risk for stroke, coronary artery 
disease and heart failure. In a large trial by Partinen and Guil-
leminault,29 OSA patients were twice as likely to have hyper-
tension, three times as likely to have ischemic heart disease 
and had four times as much cerebrovascular disease compared 
with the general population. The increased risk of CVD is not 
the only reason for increased mortality and morbidity of the 
syndrome. Automobile crashes and work-related accidents 
are other possible causes of enhanced mortality in patients 
with OSA. Masa et al30 reported that habitually sleepy drivers, 
with disturbances in sleep architecture caused by respiratory 
disorders, have a higher incidence of crashes and the incidence 
depends on the AHI. Findley et al31 found that the accident 
rate in OSA patients decreased after treatment with CPAP. 
M e C H A N i S M S  L i N K i N G  S L e e P  A P N e A 
T o  C H R o N i C  C A R d i o v A S C U L A R 
d i S e A S e
Several mechanisms have been implicated in the associa-
tion of sleep apnea with chronic cardiovascular disease (CVD), 
such as sympathetic activation, thrombophilia, a pro-inflam-
matory response, endothelial dysfunction, and propensity to 
metabolic disorders (Fig. 2). 
S y M PA T H e T i C  A C T i v i T y
The activity of the sympathetic nervous system is abnormal 
in patients with sleep apnea.32 During hypoxemia and apnea 
the sympathetic nervous activity is increased and reaches its 
peak at apnea termination and arousal from sleep, with blood 
pressure reaching levels as high as 240/130 mmHg toward 
the end of apneic episodes. Patients with sleep apnea have 
higher levels of sympathetic nervous system activity and of 
circulating catecholamines even when awake and normoxic. 
Because of chronic sympatho-excitation, untreated patients 
with sleep apnea syndrome have increased resting heart 
rates, decreased heart rate variability and increased blood 
pressure variability. In patients with CVD reduced heart rate 
variability is associated with poorer outcomes although acute 
or chronic treatment with CPAP at night reverses both the 
sympathoexcitation33 and the hypertension34 associated with 
OSA. In addition to catecholamines, levels of other circulat-
ing hormones have been found to be higher in patients with 
OSA. These are renin, aldosterone and vasopressin which play 
an important role in the regulation of blood pressure and the 
effective blood volume.
C o A G U L A T i o N
There is strong evidence that sleep disordered breathing 
results in a hypercoagulable state.35 Patients with OSA have 
increased levels of total serum fibrinogen.36,37 Fibrinogen 
enhances thrombosis and atherosclerosis by affecting platelet 
aggregation and blood viscosity. Platelet aggregability is pro-
portional to the levels of circulating catecholamines. Shortly 
after arousal there is a surge in plasma catecholamines and a 
simultaneous increase in platelet activation which can explain 
the peak occurrence of stroke and acute cardiovascular events 
early in the morning. Hui et al38 confirmed increased platelet 
activation in 42 patients with OSA (AHI >10) compared to a 
non-OSA, age- and body mass index- matched control group. 
They also concluded that CPAP therapy reduced platelet ac-
tivation at one night and at three months of follow-up. More 
studies are needed to confirm that treatment of OSA may be 
cardioprotective. In addition to these abnormalities, fibrino-
lytic activity is reduced and plasminogen activator inhibitor is 
elevated in OSA patients. 
In a trial by Winnicki et al39 the effects of severe repetitive 
hypoxemia on serum erythropoietin were studied. Untreated 
patients with severe OSA had a higher level of serum eryth-
ropoietin which decreased after CPAP treatment. Increased 
levels of erythropoietin and concomitant increases in hema-
tocrit and blood viscosity may be another possible explanation 
for hypercoagulability in OSA patients.
i N F L A M M A T i o N
Inflammation is an important component in the pathogen-
esis of atherosclerosis and the progression of CVD. Repeated 
hypoxia, which is the major pathophysiological event in sleep 
apnea, provokes the production of inflammatory cytokines, 
such as tumor necrosis factor–a (TNFa), interleukin (IL)-6 
and an increase in adhesion molecules, serum amyloid A- and 
C-reactive protein levels (CRP).40 Both CRP and IL-6 are 
FiGURe 2. Association of obstructive sleep apnea with cardio-
vascular disorders and possible mechanisms leading to athero-
sclerosis and progression of cardiac and vascular pathology.
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considered to be important risk factors for atherosclerosis 
and coronary artery disease. Plasma levels of these substances 
increase in OSA and decrease with CPAP therapy.41 Levels 
of circulating intercellular adhesion molecule (ICAM)-1 and 
vascular cell adhesion molecule (VCAM)-1 which are also 
markers of inflammation, have been found increased in OSA 
patients,42 while Zhang et al43 have observed decreased levels 
of the anti-inflammatory adipokine and adiponectin in OSA.
Homocysteine and cysteine which are regarded as cardio-
vascular risk factors are also evaluated in different studies. 
Plasma levels of homocysteine are elevated in OSA patients 
regardless of the presence of cardiac dysfunction,44 while 
cysteine levels were found increased in patients with OSA 
and decreased significantly after 6 months of effective CPAP 
therapy.45 Kokturk et al46 have shown that OSA patients with 
and without CVD have significantly higher levels of homo-
cysteine when compared with patients with CVD without 
OSA, and serum homocysteine levels were independently 
associated with the severity of OSA. 
The sleep apnea syndrome is characterized by repeated 
nocturnal episodes of apnea and hypoxemia, which are fol-
lowed by arousals and reoxygenation. This circle leads to 
production of highly reactive free oxygen radicals from the 
polymorphonuclear neutrophils. Exposure of the vascular 
wall to ischemia-reoxygenation injury and free oxygen radicals 
may induce oxidative stress to the endothelium resulting in 
increased risk for atherosclerosis. Patients with OSA have 
been found to have markedly enhanced neutrophil superoxide 
generation that decreases with CPAP therapy.9
e N d o T H e L i A L  d y S F U N C T i o N
Hypoxia and hypercapnia possibly stimulate the release 
of vasoactive substances that cause damage to the vascular 
endothelium in patients with sleep apnea. Endothelin-1 for 
example is a vasoconstricting substance synthesized in the 
endothelium which increases in OSA patients and decreases 
with CPAP therapy. In addition to this finding, patients with 
OSA have impairment of the endothelial function, even in 
the absence of any overt cardiovascular disease. Endothelial 
dysfunction can be expressed by reduced vasodilating response 
to acetylcholine and isoproterenol.47 Zhang et al48 demon-
strated the effect of CPAP therapy on endothelial dysfunction 
in patients with OSA and coronary artery disease, by means 
of measuring morning plasma nitric oxide, endothelin levels, 
and total ischemic burden of the myocardium. Their conclu-
sion was that CPAP treatment plays an important role in the 
improvement and protection of endothelial function and 
myocardial ischemia. 
Different metabolic and molecular mechanisms are im-
plicated in the pathogenesis of endothelial dysfunction as a 
consequence of hypoxia in patients with OSA. For example, 
reduced levels of circulating nitric oxide (NO) in OSA patients 
are probably related to depressed nocturnal synthesis of NO 
due to reduced oxygen supply, suppressed transcription of the 
endothelial NO synthase gene and elevated NO synthase in-
hibitors.49 Vascular endothelial dysfunction in OSA, before and 
after treatment with CPAP, was assessed in 10 male patients 
aged 36-69 years old by measuring flow mediated vasodilation 
of the brachial artery and plasma concentration of asymmetric 
dimethylarginine (ADMA).50 ADMA is an endogenous in-
hibitor of endothelial NO synthase and its levels are elevated 
in patients with cardiovascular risk factors including hyper-
lipidemia, hypertension, diabetes and hyperhomocysteinemia. 
The conclusion of this study was that CPAP therapy improves 
endothelial function by decreasing ADMA concentration and 
thereby augmenting NO production. However, several studies 
on the endothelial responses to endogenous vasodilators, such 
as NO, have led to conflicting results. 
Levels of vascular endothelial growth factor (VEGF), a 
glucoprotein that induces the proliferation of endothelial cells, 
increases vascular permeability and enhances production of 
NO and prostacyclin have been estimated in OSA patients with 
mixed results. Some but not all investigators have found higher 
levels of VEGF in subjects with OSA and regarded hypoxia 
and oxygen desaturation as the stimuli for this elevation.51-53 
Elevated levels of serum VEGF in OSA patients are not as-
sociated with the severity of the disease but with patient’s age54 
and decrease with CPAP therapy.55
Intercellular adhesion molecule (ICAM) 1, VCAM 1, E-
selectin and matrix metalloproteinase-9, substances involved 
in the development of atherosclerosis, are elevated in OSA 
patients and decrease after CPAP treatment.56 Abnormal 
leukocyte aggregation to the endothelium, increased expres-
sion of CD15 and CD11c monocytes and increased adhe-
sion of monocytes in patients with OSA, are other possible 
mechanisms for atherogenesis.9 Endothelial dysfunction is 
often related to hypertension, hyperlipidemia, diabetes and 
smoking. Sleep apnea may be an independent risk factor for 
the development of endothelial dysfunction, despite its link 
to the above mentioned comorbidities.
M e T A B o L i C  d i S o R d e R S
A large number of studies suggest an independent and 
causal relationship between OSA and metabolic syndrome, 
which further increase cardiovascular risk since the metabolic 
syndrome is recognized as a risk factor for cardiovascular mor-
bidity and mortality. Patients with OSA usually have obesity 
with central adiposity, glucose intolerance, dyslipidemia, and 
hypertension. Since these abnormalities are the major charac-
teristics of the metabolic syndrome, it has been suggested that 
its definition - also known as syndrome X - should include OSA 
(syndrome Z)57 as an additional vascular risk factor.
The prevalence of metabolic syndrome is higher in patients 
with OSA than in the general population (15-20% for Europe-
ans) or in obese subjects without OSA; the studies published 
todate estimate that the risk of metabolic syndrome in OSA 
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patients is at least 5-fold compared with controls.58 Coughlin 
and colleagues59 suggested that the prevalence of metabolic 
syndrome defined by the National Cholesterol Education 
Program (NCEP) is about 40% greater in patients with OSA, 
while Papanas et al60 have shown that among men with meta-
bolic syndrome, who are free from comorbidities and report 
symptoms suggestive of sleep-disordered breathing, high 
serum glucose is associated with a significant increase in the 
frequency of OSA, even after adjustment for body mass index.
The metabolism is affected by OSA indirectly because 
the amount and/or quality of sleep are decreased resulting in 
increased evening cortisol, sympathetic activation and insulin 
resistance.58 Obesity affects 60 to 90% of OSA patients and 
weight loss ranging from 9 to 18% of body weight was associ-
ated with reduction in the AHI by 30 to 75%.61 In the general 
population snoring was shown to be a risk factor for the devel-
opment of diabetes over 10 years independently of confound-
ing factors.62 The Sleep Heart Health Study, performed in 2656 
individuals showed that sleep-related hypoxemia is associated 
with glucose intolerance independently of age, sex, body 
mass index and waist circumference63 and OSA severity was 
associated with the degree of insulin resistance after adjust-
ment for obesity. The Wisconsin Sleep Study13 demonstrated 
a significant cross-sectional association between OSA and 
type 2 diabetes for all degrees of OSA, which persisted for 
moderate to severe OSA after adjustment for obesity. Sleep 
restriction was also shown to be associated with reduced leptin 
(a hormone that suppresses appetite), increased appetite and 
resistance to the metabolic effects of leptin.64 In animal studies 
it has been demonstrated that leptin could prevent respiratory 
depression in obesity, suggesting that a deficiency in leptin 
levels or activity may induce hypoventilation in obese subjects. 
Alterations in glucose metabolism are also encountered 
in OSA patients without diabetes; patients with OSA have 
hyperinsulinemia, fasting hyperglycemia and higher levels of 
glycosylated hemoglobin. Obstructive sleep apnea is regarded 
a highly prevalent comorbidity of type 2 diabetes and it has 
been proved that increasing severity of OSA is associated 
with poorer glucose control, independently of adiposity or 
other confounders.65 The treatment of choice for OSA, CPAP, 
both ameliorates breathing disturbances and improves several 
markers of glucose metabolism and insulin resistance, such 
as glycated hemoglobin, fasting glucose / insulin, and insulin 
resistance.66 In type 2 diabetic patients with OSA observational 
studies using continuous glucose monitoring techniques have 
reported positive effects of CPAP on glycemic control, already 
present during the first night of treatment, as variability of 
glycemic values decreased compared with baseline conditions. 
Although the effects of CPAP treatment on the metabolic 
syndrome are controversial, it was recently suggested that 
treatment indications of CPAP should be reevaluated; for 
OSA patients who meet the criteria of metabolic syndrome 
initiating CPAP treatment at lower AHI levels may contribute 
to the prevention of CVD development.67 
Other markers of glucose metabolism have been assessed 
in OSA patients, such as insulin growth factor (IGF)-1 and 
adiponectin. A high IGF-1 concentration is predictive of de-
creased risk of type 2 diabetes and impaired glucose tolerance, 
whereas low IGF-1 concentrations were found to be associ-
ated with increased risk of CVD.68 The complex interactions 
between IGF-1, its binding proteins and insulin sensitivity 
promote IGF-1 as an important regulator of glucose homeo-
stasis. While fasting insulin and blood glucose are subject to 
short-term changes, IGF-1 is a more stable variable subject to 
long-term regulation. Adiponectin is known to counteract the 
effects of insulin resistance, and the effects of OSA treatment 
on adiponectin have been assessed with controversial results. 
Some studies found increased adiponectin after 1 night or 2 
weeks of CPAP treatment, while other studies found no change 
in adiponectin levels after OSA treatment for 1 night or 1–3 
months.58 Research should elucidate the interactions between 
metabolic syndrome and OSA and define their implications. 
T R e A T M e N T
Given the increased morbidity and mortality among pa-
tients with SAHS,69 an effective treatment must be started as 
soon as the diagnosis is made. The goal of therapy70 is to restore 
sleep architecture and thus improve daytime functioning. Ef-
fective treatment results in a decrease in AHI and an increase 
in oxyhemoglobin saturation. The first therapeutic approach 
to a patient with a mild degree of sleep apnea includes weight 
loss, avoidance of the supine posture during sleep-positional 
therapy, abstinence from alcohol, tobacco and sedatives and 
avoidance of sleep deprivation. Treatment of comorbid con-
ditions, such as hypothyroidism, should also be considered.
Various drugs have been investigated for the management 
of OSA with no success. Acetazolamide, theophylline, nico-
tine, opium antagonists and medroxyprogesterone have been 
used to increase respiratory drive. Clonidine has been used in 
order to reduce REM sleep as well as various antidepressants. 
The aim of pharmacotherapy is among others to activate the 
upper airway dilator muscles. Most of the drugs have been 
found to be scarcely effective and those with good results in 
some patients, i.e. acetazolamide and protriptyline, have been 
associated with intolerable side effects. The use of stimulants, 
however, such as modafinil may be considered as an adjunctive 
therapy for daytime sleepiness.71 Given the fact that various 
inflammatory mediators are involved in the pathogenesis and 
progression of CVD in OSA patients, drugs like aspirin and 
statins, which lower these measures of inflammation, can be 
used with anticipated benefit.
First-line therapy for moderate to severe sleep apnea syn-
drome is positive airway pressure therapy, which is associated 
with 64% reduction of cardiovascular risk and cardiovascular 
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outcomes independently from age and preexisting comor-
bidities.72 Therapy with CPAP (Fig. 3) can be applied in three 
forms with continuous, bilevel and autotitrating function. Nasal 
CPAP functions as a pneumatic stent that prevents the col-
lapse of the pharynx due to negative inspiratory pressure. In 
this manner the upper airway remains open during inspiration 
and nocturnal oxygenation, sleep architecture and daytime 
functioning are improved. In order to increase tolerance of 
positive airway pressure treatment in patients with OSA, bi-
level assisted ventilation and autotitrating positive airway pres-
sure have been used as alternatives, with similar improvement 
in daytime sleepiness in most studies. Autotitrating positive 
airway pressure continuously adjusts pressure to patient’s 
needs, thus the overall mean airway pressure can be reduced.73 
Bilevel assisted ventilation allows independent adjustment 
of inspiratory and expiratory pressures and is indicated for 
patients who experience discomfort exhaling against positive 
pressure with CPAP, or have restrictive thoracic disorders, 
chronic obstructive pulmonary disease or central sleep apneas.
Compliance to CPAP therapy ranges from 50% to 100%.74 
Reasons for no adherence are noise from the device, bed 
partner intolerance, mask discomfort, skin abrasions, conjunc-
tivitis, mask rubbing, nasal congestion, rhinorrhea, sneezing, 
epistaxis, nasal dryness, sinus discomfort, chest discomfort, 
aerophagia, claustrophobia and difficulty exhaling. Finally, 
pneumothorax and pneumocephaly are rare side-effects. 
Compared with other therapeutic approaches, nasal CPAP is 
a cost effective treatment of choice for sleep apnea syndrome. 
Effective CPAP treatment lowers apnea-hypopnea index as 
shown in many clinical trials. In a study designed by Clark et al 
there was a 60% decrease in the AHI in OSA patients treated 
with nasal CPAP.75 D’Ambrosio et al76 studied the impact of 
nasal CPAP therapy on quality of life in OSA patients. After 
8 weeks of treatment with CPAP there was a significant im-
provement in all aspects of life quality, such as vitality (75%), 
social functioning (95%) and mental health (96%). 
Oral devices are considered a treatment option for snor-
ing, but they should not be recommended in CSA and patients 
with severe OSA. These devices displace the tongue and jaw 
forward in order to augment the posterior pharyngeal area. 
Compared to CPAP, oral devices have poorer results even in 
mild to moderate OSA. Surgical approaches are recommended 
for patients with discrete craniofacial abnormalities rather 
than simply obese patients. In selected patients, and in hands 
of experienced medical staff, the success rate can be as high 
as 90%. Complications include bleeding, infections, upper 
airway obstructions caused by surgical edema, hematomas 
and facial anesthesia. An effective alternative to therapy in 
morbidly obese patients is tracheotomy. Although it is easy 
to perform, hygiene issues and inconvenience do not allow 
its widespread use.
C o M o R B i d  C o N d i T i o N S  A S S o C i A T e d 
w i T H  S L e e P  A P N e A
The pathophysiological phenomena that take place in sleep 
apnea lead to increased sympathetic activation, increased oxi-
dative stress, inflammation, vascular endothelial dysfunction, 
increased platelet aggregability and metabolic dysrhythmia. 
These mechanisms may be implicated in the pathogenesis and 
promotion of CVD, such as hypertension, coronary artery dis-
ease, congestive heart failure, systolic and diastolic dysfunction 
of the left ventricle, cardiac arrhythmias, stroke, pulmonary 
hypertension and all-cause mortality.77
H e A R T  FA i L U R e
Sleep-related breathing disorders are common in heart fail-
ure. Sleep apnea in patients with CHF can be obstructive (due 
to upper airway collapse), central (characterized by Cheyne-
Stokes respirations) or a combination of both. In the Sleep 
Heart Health Study, OSA was found to be an independent risk 
factor for CHF.63 In this study patients with AHI >11 were 
found to have a 2.38 relative risk for CHF, which was higher 
for OSA than all other cardiovascular diseases. It has been 
noted that at least 45% of patients with systolic heart failure 
have an AHI ≥10 and at least 40% have an AHI ≥15.78 In two 
large studies of patients with CHF, the prevalence of OSA 
was 11% among 81 patients and 32% among 450 patients.79,80 
Among patients with heart failure the prevalence of OSA was 
greater in men (38% versus 31%; P <0.005) and risk factors 
for OSA were also different between men and women; among 
men only body mass index and among women only age were 
significantly associated with OSA. Chan et al81 estimated that 
approximately 50% of patients with isolated diastolic heart 
failure have an AHI of at least 10 per hour. 
Cheyne-Stokes breathing and CSA are also common 
FiGURe 3. An example of a mask providing continuous positive 
airway pressure (CPAP), which is the first line therapy for the 
sleep apnea-hypopnea syndromes (SAHS).
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among patients with CHF with a prevalence estimated to be 
as high as 30% - 40%. Moreover, they are highly prevalent in 
patients with left ventricular dysfunction even without overt 
heart failure and is a common disorder in men, but a rare one 
in women with CHF. It has been reported by Tkacova et al82 
that some patients with CHF present with shifts from OSA to 
CSA, which have been attributed to overnight episodes of a 
reduction in PCO2, episodes of an increase in circulatory delay 
and deterioration in cardiac function; this finding implies that 
abolition of OSA would improve nocturnal hemodynamic 
function in patients with CHF. 
Sleep disordered breathing predisposes to progression of 
heart failure, through activation of adrenergic and inflamma-
tory mechanisms that worsen prognosis. Central sleep apnea is 
associated with a poorer outcome, increased arrhythmic risk, 
cardiac transplantation and death, while OSA is associated 
with both systolic and diastolic dysfunction of the left ventricle. 
Yet to be established is whether OSA can cause heart failure 
or increase mortality in heart failure patients. A recent study 
suggested that the presence of untreated OSA (AHI >15) in 
patients with heart failure is associated with increased risk of 
death compared with patients with an AHI <15 independently 
of other confounding factors83. 
Obstructive sleep apnea potentially contributes to progres-
sion of heart failure through different mechanisms,78,84 the most 
common been hypertension. Hypoxemia, catecholamine surge, 
nocturnal rise of blood pressure and daytime hypertension 
predispose to hypertensive heart failure. Multiple mechanisms 
contribute to systolic dysfunction. Inflammatory cytokines 
affect directly myocardial contractility. Peripheral vasocon-
striction due to sympathetic surges results in an increase of 
afterload. The increase in negative intrathoracic pressure, 
which is caused by repeated respiratory efforts against the oc-
cluded upper airway, leads to abrupt changes in cardiac trans-
mural pressure and concomitant increase in wall stress. It also 
increases venous return to the right ventricle. A leftward shift 
of interventricular septum affects diastolic filling of the left 
ventricle. The combination of increased afterload and reduced 
preload leads to a reduction in stroke volume. Regarding dia-
stolic dysfunction, hypertension and effects of endothelin and 
catecholamines on cardiac structure play the most important 
role. In several case reports, patients with OSA appear to have 
acute nocturnal pulmonary edema with normal left ventricular 
systolic function. These cases suggest that OSA and its adverse 
effects can cause acute left ventricular failure in susceptible 
individuals. After induction of recurrent obstructive apneas to 
anesthetized dogs, Fletcher and colleagues85 demonstrated the 
development of interstitial pulmonary edema.
Congestive heart failure itself can contribute to the devel-
opment of OSA. Patients with heart failure are exposed to pe-
riodic breathing. During periodic breathing, respiratory drive 
declines and as a result of this, pharyngeal dilator muscles drive 
declines as well, leading to collapse of the upper airway. The 
critical pressure, below which collapse occurs, is the pressure 
of the diaphragm. Another possible mechanism predisposing 
patients with CHF to OSA is edema. Edema may involve the 
neck and the soft tissues of pharynx and can lead to further 
narrowing of the airway, particularly in the supine position. 
Recent observational data suggest a trend to a lower mor-
tality rate in heart failure patients with CPAP-treated OSA 
compared with untreated OSA, although randomized clinical 
trials are needed to test the hypothesis whether CPAP treat-
ment of patients with OSA and heart failure leads to mortality 
benefit. Patients with left ventricular systolic dysfunction and 
OSA who were treated with cardiac resynchronization therapy 
(CRT) showed reduction of AHI and CRT-mediated reduc-
tion of mitral regurgitation86 while lack of AHI reduction after 
months of CRT was regarded as an independent risk factor of 
death and major cardiac events during follow-up87; yet further 
studies are needed to further elucidate this issue. 
H y P e R T e N S i o N
Hypertension is highly prevalent in individuals with OSA 
with estimates ranging from 50% to 90%,88 whereas 30% and 
more of middle-aged men with hypertension also have OSA 
which is underdiagnosed. Most of the literature agrees that 
OSA is strongly associated with hypertension and that there 
is a causal relationship between them, independent of pos-
sible confounding variables such as obesity, male gender, age, 
coexisting CVD, tobacco and alcohol use. The relationship 
between OSA and systemic hypertension89 can be explained 
by acute and chronic increases in sympathetic nerve activity 
as a response to hypoxia. Patients suffering from respiratory 
disturbances during sleep have been found to have higher 
levels of sympathetic activity and circulating catecholamines 
not only during the apneic episodes but also while awake. In-
creased sympathetic activity results in a concomitant increase 
in heart rate, cardiac output, peripheral vascular resistance 
and tubular sodium reabsorption in the kidney, mechanisms 
which may contribute to elevated blood pressure. Moller et al90 
performed 24-hour blood pressure monitoring and measured 
plasma levels of vasoactive hormones such as renin, angioten-
sin II, aldosterone, atrial natriuretic peptide, brain natriuretic 
peptide, vasopressin and endothelin-1 in 24 OSA patients and 
18 matched controls. Patients with OSA were found to have 
higher blood pressure and heart rate, while there was no sleep-
related blood pressure drop, and higher levels of angiotensin II 
and aldosterone. After 14 months of CPAP therapy there was 
reduction in blood pressure and plasma renin and angiotensin 
II concentrations. Tsioufis et al91 evaluated aortic stiffness of 
newly diagnosed hypertensive patients with or without OSA by 
means of carotid-femoral pulse wave velocity measurements 
and concluded that OSA has an incremental effect on aortic 
stiffening, as it accelerates vascular damage and increases 
cardiovascular risk.
In a healthy individual blood pressure drops during the 
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night about 15% below daytime levels. This pattern is similar 
to hypertensive patients named as “dippers”. In contrast, 
OSA patients are “non dippers”. Portallupi and associates92 
described the presence of unsuspected OSA in 10 of 11 patients 
with a “nondipping” pattern of nocturnal blood pressure and 
daytime hypertension, but in none of 10 “dipping” hypertensive 
patients. This study implies that many hypertensive patients, 
who do not demonstrate a fall in nocturnal blood pressure 
have undiagnosed OSA. “Nondipping” is a condition associ-
ated with a higher risk of cardiovascular complications, even 
in the absence of daytime hypertension, therefore the debate 
about whether OSA leads to daytime hypertension may not 
be of importance.
Nieto et al93 proposed vascular dysfunction as a possible 
mechanism for the correlation between OSA, hypertension and 
CVD. In the “Wisconsin Sleep Cohort Study”, a large popula-
tion study with 893 subjects, patients with an AHI >15, had an 
odds ratio of 4.5 for developing hypertension, compared with 
those without sleep apnea.94 When adjusted for confounding 
variables, the relative risk was 2.9 indicating that OSA is an 
independent risk factor for hypertension. In another study of 
1741 patients, OSA was found to be independently associated 
with elevated blood pressure in both men and women, after 
adjustment for possible co-variables such as age, body mass 
index, gender, menopause, hormone replacement therapy, 
alcohol use, smoking and race.95 The ‘Sleep Heart Health 
Study’ concluded that mean systolic and diastolic blood pres-
sure increased significantly with SAHS, mainly for patients 
with a baseline AHI > 30, although some of this association 
was explained by body mass index.96,97 
Treatment with CPAP reduces nocturnal blood pressure in 
OSA patients98 but its effect on daytime hypertension remains 
controversial. Four major recent studies describe the effects 
of CPAP treatment on blood pressure.99 In those studies, 
only severe OSA was associated with substantial reduction 
in blood pressure after CPAP therapy, while patients with 
minimal symptoms and few apneic events did not benefit from 
treatment. Faccenda et al100 studied 68 patients with OSA and 
hypertension and demonstrated a 1.5 mmHg fall in diastolic 
blood pressure after initiation of nasal CPAP therapy. Dims-
dale and coworkers101 demonstrated a fall in daytime blood 
pressure and a smaller effect on nocturnal blood pressure in 
39 patients treated with CPAP. They also found a reduction in 
daytime plasma norepinephrine concentrations and nocturnal 
urinary norepinephrine levels. A fall in daytime blood pressure 
was also found in the placebo group using nasal CPAP. In a 
study at the Oxford Centre for Respiratory Medicine by Pep-
perell et al102 therapeutic nasal CPAP reduced mean arterial 
pressure by 2.5 mmHg whereas subtherapeutic nasal CPAP 
increased blood pressure by 0.8 mmHg. Such a benefit was 
seen in both systolic and diastolic blood pressure, during sleep 
and wake and was larger in patients with more severe OSA. 
According to Barbe et al,103 patients having CPAP treat-
ment for more than 5.6 hours/night during one year demon-
strate a small but rather beneficial reduction in blood pressure 
(systolic blood pressure by 1.89 and diastolic blood pressure 
by 2.19). Finally, Becker et al104 showed a substantial decrease 
in daytime and nocturnal hypertension in patients with severe 
OSA (mean AHI 64) receiving full treatment with CPAP. 
Although the initiation of partially therapeutic nasal CPAP 
led to a reduction in AHI of 50%, no blood pressure reduction 
was seen in the partially treated group. This study emphasizes 
the importance of complete resolution of OSA and suggests 
that there are moderate and variable effects of CPAP on blood 
pressure in patients with OSA; patients with more severe OSA, 
difficult to control hypertension and better CPAP compliance, 
have more substantial blood pressure reduction with CPAP. 
Three meta-analyses have been published recently regarding 
the effect of treating OSA with CPAP on blood pressure. 
Overall a modest but significant net reduction in blood pres-
sure was found (≈2 mmHg) and CPAP was found to reduce 
systolic blood pressure by ≈3 mmHg (P = 0.10) and diastolic 
pressure by 2 mmHg (P = 0.05) in patients with more severe 
OSA (AHI >30).105-107 
The Joint National Committee (JNC VI) in 1997 suggested 
that OSA should be excluded as a possible contributory factor 
to resistant hypertension when obesity coexisted. Nevertheless, 
the most recent set of guidelines (JNC VII) included OSA as 
first in the list of causes of hypertension.108 Among antihy-
pertensive agents including atenolol, amlodipine, enalapril, 
hydrochlorothiazide and losartan, β-blockers were found to be 
most effective in lowering daytime blood pressure in hyperten-
sive OSA patients, but they were found to have little effect on 
nocturnal blood pressure. This finding is compatible with the 
hypothesis that sympathetic overactivity is the key mechanism 
in the development of hypertension in OSA patients. There 
is no current evidence that any specific antihypertensive drug 
attenuates sleep apnea severity although a recent report sug-
gests that cough and rhinopharyngeal inflammation induced by 
angiotensin-converting enzyme inhibitors may worsen the AHI 
which decreases when the drug is discontinued.109 Resolution 
of OSA with tracheostomy was associated with a reduction in 
nocturnal blood pressure. The data from studies of OSA imply 
that many cases of idiopathic hypertension and hypertension 
resistant to therapy may actually be secondary to undiagnosed 
and untreated sleep apnea syndrome. When left untreated, 
OSA leads to structural changes in the vasculature to the 
point that they become irreversible. This is why treatment of 
OSA is ineffective in lowering blood pressure in some cases.
S T R o K e
The reported prevalence of sleep apnea after stroke varies 
between 50% and 70%. There is convincing evidence that sleep 
apnea is associated with the occurrence of stroke but further 
studies are needed in order to confirm a causative relationship 
independent of other factors. In the Sleep Heart Health Study 
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there was a small but significant increase in the prevalence of 
stroke among OSA patients110 and in a cross-sectional study 
of Japanese men, brain magnetic resonance imaging revealed 
silent brain infarction in 25% of patients with moderate to 
severe OSA.111 Patients with stroke have a higher incidence of 
OSA as shown in various studies112,113 and post-stroke AHI is 
high for patients maintained in the recumbent position (espe-
cially within the 24 hours of stroke). Yet a recent study from 
Sweden noted that among 132 patients who were admitted 
for in-hospital rehabilitation and underwent overnight cardi-
orespiratory sleep monitoring, only 23 patients had OSA – 28 
patients had CSA and 2 patients had mixed apnea.114
Many patients who suffered a stroke have coexisting sleep 
apnea which can affect potential recovery.115 A study by Parra 
et al116 focused on the impact of sleep disordered breathing on 
two-year survival of patients with a first ischemic attack. The 
investigators concluded that sleep disordered breathing is an 
independent risk factor for increased mortality after a first 
stroke. For each additional unit of AHI there is a 5% increase 
in mortality risk, suggesting an association between mortality 
rate and severity of sleep apnea.
Obstructive sleep apnea could predispose to stroke through 
blood pressure swings, reduction in cerebral blood flow, im-
paired endothelial function, prothrombotic/ proinflammatory 
states, hypercoagulability and impaired cerebral hemodynam-
ics.117 Patients with OSA have an abnormal cerebral autoregu-
lation of blood flow and a diminished vasodilator response to 
hypercapnia. During apneas, hypoxia and hypercapnia lead to 
a reduction of cerebral blood flow. Vasoconstriction, due to 
diminished response of cerebral vessels to hypercapnia, results 
in a significant rise in intracranial pressure. These phenomena 
cause a further decrease in cerebral perfusion in areas of the 
brain with already borderline or poor circulation while blunted 
cerebral blood flow in patients with OSA has been reported 
to normalize after 4-6 weeks of CPAP therapy.118
It remains unclear whether sleep apnea following a stroke 
is a consequence of the stroke rather than a preexisting condi-
tion. When sleep apnea is present after a stroke, it can further 
affect daytime functioning and rehabilitation of the patient. 
Apnea-related hypoxia can lead to the production of γ–ami-
nobutyric acid, a neuroinhibitory peptide which can further 
compromise cognition.119 In older studies it has been suggested 
that central apneas are associated with bilateral hemispheric 
and brain stem infarction. More recent trials suggest that the 
occurrence of OSA may precede the occurrence of stroke; 
researchers have found that stroke severity does not predict 
the presence of severity of OSA and, when present, it is a 
sign of underlying cardiac dysfunction.120 Stroke may promote 
central apneas only in the immediate post-stroke period, when 
brain inflammation and edema are present. As these resolve, 
so do central apneas.
Recent 10-year follow-up data from patients with stroke, 
showed an increased risk of death in patients with OSA (ad-
justed hazard ratio 1.76; P = 0.03) independently of age, sex, 
body mass index, smoking, hypertension, diabetes mellitus, 
atrial fibrillation, Mini-Mental State Examination Score and 
Barthel Index of Activities of Daily Living. Post-stroke mor-
tality was not also increased for CSA patients.121 Obstructive 
sleep apnea in the post-stroke patients reduces motivation, 
decreases cognitive capacity and may increase the risk of re-
current stroke and death. The application of CPAP offers to 
patients with OSA the opportunity to increase the rehabilita-
tion potential after stroke but Bassetti et al122 found that only 
15% of patients with sleep apnea and acute ischemic stroke 
continued CPAP chronically.
C o R o N A R y  A R T e R y  d i S e A S e
Obstructive sleep apnea is a common condition among 
patients with coronary artery disease (CAD); its prevalence 
has been shown to be up to 2-fold greater than in non-CAD 
subjects. In a study of >200 consecutive patients without a 
history of CAD who underwent electron-beam computed 
tomography within 3 years of polysomnography, the median 
coronary artery calcification score (Agaston units) was 9 in 
OSA and 0 in non-OSA patients (P <0.001),123 confirming an 
independent association between subclinical CAD and OSA. 
The presence of OSA is associated with nocturnal angina, 
nocturnal ST-segment depression and adverse outcomes in 
these patients. Hung and his associates124 described OSA as 
a strong risk factor for myocardial infarction, such as obesity, 
smoking and hypertension. In the Sleep Heart Health Study 
OSA was found to be an independent risk factor for CAD. 
However, the study showed only a modest increase in the 
odds ratio of CAD in patients with severe OSA compared 
with controls. Patients with OSA have ST-segment changes 
indicative of ischemia during sleep that is proportional to 
oxyhemoglobin desaturation and severity of OSA. Various 
studies have reported a prevalence of ST-segment depression 
ranging from 20% to 100%.125-127
The mechanism of provoked ischemia in OSA is related to 
increases in myocardial oxygen demand during the post-apneic 
surge in blood pressure and heart rate, at a time when oxygen 
saturation reaches its nadir. The risk of myocardial infarction 
is greater at this time. Usually the patient rises from sleep with 
complaints of angina. The acute changes that provoke ischemia 
in OSA are hypoxemia, hypercapnia, sympathetic activation, 
surges in blood pressure and post-apneic tachycardia. Chronic 
mechanisms involve daytime hypertension, production of vaso-
active and trophic substances such as endothelin, activation of 
inflammatory processes and hypercoagulable state. Reduced 
capacity for fibrinolysis increases the risk of occlusion. All these 
mechanisms contribute to the development and progression 
of CAD. It is not yet known whether OSA causes nocturnal 
ischemia in the absence of CVD. On the other hand, changes 
of cardiac function after a myocardial infarction provoke the 
development of OSA or affect its severity.
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Obstructive sleep apnea is a predictor of poor outcome in 
patients with CAD. In a study of 62 patients with known CAD, 
those having OSA had a significantly higher mortality (38%), 
compared to those without OSA (9%), during a five-year 
follow up after adjusting for other confounding variables.128 
Pecker et al129 showed that 37% of patients with OSA initially 
suffered from CVD compared with only 7% in patients who 
received proper treatment. A recent study of >500 subjects 
reported that people with OSA are more likely than those 
without OSA to have a family history of premature death from 
CAD independently of gender, body mass index and personal 
history of CAD130. It seems that OSA affects the timing of sud-
den cardiac death (more than half of sudden cardiac deaths 
in OSA patients occur during the sleeping hours 10PM and 6AM 
while non-OSA patients experience cardiac death between 6 
and 11AM) although it is not known whether OSA increases 
the risk of sudden cardiac death.131 
A long-term prospective study evaluated the benefits of 
OSA treatment on the rate of CAD. Investigators concluded 
that treatment of patients is associated with a decrease in the 
occurrence of new cardiac events and an increase in time to 
such events,132 while older studies have shown that treatment 
with CPAP reduces the total duration of ST-segment depres-
sion in subjects with sleep apnea.133
C A R d i A C  A R R H y T H M i A S
The repetitive oscillations between sympathetic and para-
sympathetic predominance in OSA during sleep, depending 
on the ventilatory phase of the apneic episode and the phase 
of sleep, provide the perfect milieu for the development of 
cardiac arrhythmias. When parasympathetic tone predomi-
nates, bradyarrhythmias may occur; when sympathetic tone 
predominates, both atrial and ventricular tachyarrhythmias 
may occur.134 Arrhythmias in OSA patients result from the 
dysfunction of the autonomic nervous system on the heart 
and are usually not related to primary lesions of the sinus 
node, atrioventricular node or His–Purkinje system. The most 
commonly seen arrhythmia in OSA patients is the periodic 
variability of the cardiac rhythm which is characterized by 
bradycardia at the beginning of apnea followed by tachycardia 
at the end of the apneic event. The severity of bradycardia 
depends on the degree of hypoxemia. The basic mechanism 
implicated in this type of arrhythmia is hypoxia, leading to 
changes in the autonomic balance. Convincing evidence for 
this is the abolition of the arrhythmia with atropine and after 
tracheotomy. Moreover, the periodic variability of the cardiac 
rhythm is absent in patients with autonomic neuropathy, Shy-
Drager syndrome or patients with OSA that have undergone 
heart transplantation. 
The prevalence of bradyarrhythmias in patients with OSA 
ranges from 7 to 50% depending on the severity of OSA (num-
ber of apneic episodes, severity of associated hypoxemias) and 
the duration of cardiac monitoring. In a study of 400 patients 
with OSA sinus bradycardia, sinus pause >2.5 s and second-
degree atrioventricular conduction block were found in 7%, 
11% and 8% respectively.135 Prolonged sinus arrest up to 13 
s and Mobitz II conduction disturbances have also been ob-
served. Severe bradyarrhythmias have been associated with a 
very low oxygen saturation (<72%). Koehler et al136 concluded 
that approximately 90% of bradycardic episodes occur during 
REM sleep and during apneic episodes that lead to a 4% de-
crease in oxygen saturation. Becker et al137 reported that 7.5% 
of patients with OSA had significant bradyarrhythmias (2nd 
and 3rd degree atrioventricular block, sinus pauses >2 s) which 
were strongly correlated with OSA severity and the degree of 
nocturnal desaturation (AHI >60). By contrast, studies by Fle-
mons et al138 and the more recently Sleep Heart Health Study139 
showed no increased prevalence rates of bradyarrhythmias in 
OSA patients. In a report by Simantirakis et al140 23 patients 
with moderate to severe OSA had an insertable loop recorder 
implanted and two 24-hour Holter recordings during a period 
of 16 months; the loop recorder revealed severe cardiac rhythm 
disturbances (cardiac pauses >3 s and bradycardic episodes 
<40 bpm) in 47% while the Holter monitoring noted arrhyth-
mias in only 13% of the patients, suggesting that the observed 
rate of bradyarrhythmias in OSA patients is strongly related 
to the extent of cardiac monitoring. This study also observed 
that arrhythmic episodes tended to decrease 8 weeks after the 
initiation of CPAP and no episodes were recorded during the 
last 6 months of follow-up. 
Supraventricular tachyarrhythmias have also been associ-
ated with OSA. Correlation of atrial fibrillation and OSA is 
ascribed to various mechanisms; hypoxia and hypercapnia 
have a direct negative effect on electrical stability of the 
heart. Moreover, they activate chemoreceptors which in turn 
stimulate sympathetic nervous activity leading to vasoconstric-
tion and increased blood pressure. Afterload increases due to 
peripheral vasoconstriction, while hyperventilation against the 
occluded airway leads to an increase of venous blood return 
and of intrathoracic pressure. These mechanisms result in an 
increase of the dimensions of the atria. Obstructive sleep ap-
nea is also associated with vasoconstriction in the pulmonary 
vasculature and pulmonary hypertension. All these hemody-
namic, neurohormonal and metabolic changes, combined with 
increased circulating catecholamines, augment the risk for 
occurrence of atrial fibrillation in patients with sleep apnea. 
The increasing number of clinical reports associating sleep 
apnea and atrial fibrillation led Ghias et al141 to an experi-
mental model according to which dogs were anesthetized and 
ventilated by positive pressure respirator inducing controlled 
periods of apnea. During apnea, atrial and pulmonary vein 
programmed pacing was performed and neural activity was 
monitored from the ganglionated plexi adjacent to the right 
pulmonary veins. Recorded ganglionated plexi neural activity 
progressively increased by pacing before the onset of atrial 
fibrillation showing reproducible occurrence of atrial fibrilla-
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tion. When radiofrequency ablation of the ganglionated plexi 
of the right pulmonary artery or autonomic blockade occurred, 
atrial fibrillation inducibility was significantly inhibited. 
A study by Porthan et al142 assessed the prevalence of 
sleep apnea syndrome in subjects with “lone” atrial fibril-
lation. Although the prevalence of sleep apnea was high in 
the atrial fibrillation group (32%), it did not differ from the 
control subjects. However, in another study by Gami et al143 
the prevalence of sleep apnea in patients with atrial fibrillation 
(n=151) was significantly higher (48%) compared with patients 
(n=312) without the arrhythmia (32%) (p=0.0004, odds ratio 
2.19). In a study of 400 adults with moderate to severe OSA, 
nocturnal episodes of atrial fibrillation were observed in 3% 
of patients and all patients who received definite treatment 
of OSA had complete resolution of atrial fibrillation up to 6 
months later.135 It is estimated that ≈50% of patients present-
ing for cardioversion of atrial fibrillation have OSA compared 
to 30% likelihood of OSA in the general cardiology clinic 
population. Atrial fibrillation is frequently seen in patients 
with sleep disordered breathing and coexisting heart failure 
or coronary bypass graft surgery. The syndrome is related to 
a higher risk of recurrence of atrial fibrillation after success-
ful cardioversion.144 Patients who are treated successfully with 
pulmonary vein isolation have a 48% prevalence of OSA while 
patients with therapy-resistant symptomatic paroxysmal atrial 
fibrillation (defined as arrhythmia recurring after ≥ 2 isolation 
procedures) have higher prevalence of OSA (87%),145 a finding 
which further underlines the possibility of a causal relationship 
between the two diseases.
Up to 66% of patients with sleep apnea have ventricular 
ectopy.146 The prevalence of ventricular ectopy in OSA patients 
is higher compared to matched controls (0%-12%). Oxygen de-
saturation plays an important role for this phenomenon but the 
exact underlying mechanism is not yet fully elucidated. Shepard 
et al147 related the higher incidence of premature ventricular 
beats in sleep apnea patients to oxyhemoglobin saturation < 
60%. Nevertheless, the incidence of non-sustained ventricular 
tachycardia is equal among patients with sleep apnea and non-
apneic controls. Although sleep apnea, obstructive or central, 
in patients with heart failure is associated with worsening of the 
ejection fraction and high incidence of ventricular arrhythmias, 
the number of shocks among patients with sleep apnea and 
an implantable cardioverter defibrillator, and those having 
a defibrillator but no breathing disorders, was the same in a 
recent trial.148
Treatment with CPAP improves or even abolishes most 
of the arrhythmias. Harbinson et al149 studied 45 patients with 
OSA and AHI > 50. Disturbances of the cardiac rhythm were 
observed in 35 patients, 8 of whom had serious ones. Seven out 
of eight did not demonstrate arrhythmias after using the mask. 
Patients with significant bradycardia due to sleep apnea treated 
with CPAP have an excellent prognosis relating to the risk of 
death from syncope. Untreated OSA patients who experience 
successful cardioversion for atrial fibrillation have an 82% 
risk for recurrence of atrial fibrillation within 1 year, which 
is double the risk seen in effectively treated OSA patients.
The relationship between sleep apnea and cardiac pacing 
constitutes a significant area of research. Currently cardiac pac-
ing is not indicated, even in cases of severe bradycardia during 
the apneic episodes. According to the European Multi-Center 
Polysomnographic Study, patients with pacemakers have a 
remarkably high prevalence of SAHS150 raising the question of 
whether primary treatment of sleep apnea would have changed 
the need for pacing in some patients and suggested that paced 
patients should be evaluated for OSA because of its detrimen-
tal cardiovascular effects. Treating apnea with CPAP or with 
tracheotomy generally reduces the number of bradyarrhyth-
mias. Moreover the results of several trials suggest that atrial 
overdrive pacing reduces the number of apneic events through 
the night.151 Garrigue et al152 studied the results of overdrive 
pacing in a small number of patients with central or obstructive 
apnea (50% reduction in obstructive apneas) and concluded 
that cardiac pacing reduces AHI in both types of apnea. The 
mechanism of action of atrial pacing in central apnea relies 
on two phenomena, counteraction of parasympathetic activ-
ity and improvement of cardiac failure. The increase in heart 
rate improves cardiac output, which in turn mitigates pulmo-
nary subedema. In this way, gas exchange within the lungs is 
improved, hyperventilation is diminished and the number of 
central apneic events is reduced. In obstructive apnea, excess 
vagal tone causes muscular relaxation in the area of pharynx 
and obstruction. Pacing in this case counteracts vagal activity 
and increases the sympathetic tone. However, the effect of 
pacing in sleep apnea has not been confirmed by other more 
recent studies involving different populations153,154 and its role 
in the treatment of this syndrome needs to be further studied, 
especially for those patients who do not meet the common 
indications for implantation of a permanent pacemaker. 
Likewise, there are no data supporting the use of im-
plantable defibrillators or antiarrhythmic drugs for patients 
with ventricular arrhythmias and sleep apnea syndrome. The 
prevalence of ventricular tachycardia in OSA patients is not 
higher than non OSA subjects, whereas all reports of ven-
tricular tachycardia in this population refer to non-sustained 
ventricular tachycardia. On the other hand, patients with 
SAHS and a low ejection fraction have ventricular arrhythmias 
more often than patients with heart failure of the same degree 
but no respiratory disturbances. Finally, the indication for an 
electrophysiology study should rely only on the presence of 
daytime symptoms. 
P U L M o N A R y  H y P e R T e N S i o N
Hypoxemia causes constriction of the pulmonary vascula-
ture, and through this mechanism, raises the pulmonary vas-
cular resistance and the pulmonary artery pressure. However, 
OSA does not lead to overt pulmonary hypertension and right 
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heart failure in the absence of daytime hypoxia and coexistent 
pulmonary disease. In several studies, the prevalence of day-
time pulmonary hypertension in patients with sleep disordered 
breathing ranges from 20% to 41% without underlying lung 
disease.155,156 The degree of pulmonary hypertension in these 
studies depends on body mass index and low daytime PO2, 
rather than severity of OSA. Therapy with CPAP improves 
pulmonary hypertension and decreases pulmonary vascular 
resistance as well as pulmonary artery acute responses to 
hypoxemia. The greatest benefit of treatment with CPAP has 
been observed in patients with baseline pulmonary hyperten-
sion. In a recent randomized crossover study of 12 weeks of 
effective versus sub-therapeutic CPAP in 23 patients with OSA, 
effective CPAP was associated with decreases in echocardio-
graphic measurements of pulmonary artery systolic pressure.157 
PA T e N T  F o R A M e N  o vA L e
Patent foramen ovale (PFO) a common condition found 
in 25% of the adult population, constitutes a risk factor for 
cryptogenic stroke and a potential contributor to hypoxemia 
in patients. In patients with OSA the prevalence of PFO 
is estimated to be about 69% when assessed by means of 
contrast transesophageal echocardiography158 and could be 
further increased if contrast transcranial Doppler has been 
used in routine. Both OSA and PFO are usually undiagnosed 
in primary care practice, yet cardiologists and pulmonolo-
gists should get familiar with their association; although OSA 
patients have comparable baseline O2 saturations regardless 
of the presence of a PFO, when the Valsalva maneuver is per-
formed a significantly greater fall in O2 saturation is observed 
in patients with PFO. In a group of 209 subjects diagnosed 
with OSA, the hypothesis that oxygen desaturation index / 
apnea-hypopnea index ratio (ODI/AHI) could be a clinically 
useful screening tool in detecting OSA patients with a high 
likelihood of a PFO was tested and it was found that prevalence 
of PFO was 60% for ODI/AHI ≥0.06 and 13% for ODI/AHI 
≤0.33.159 Percutaneous occlusion with device implantation in 
PFO patients probably improves sleep apnea symptoms160,161 
but further studies should be performed in order to prove 
such a statement.
A S T H M A
Asthmatic patients with coexisting OSA and snoring ex-
perience frequent nocturnal exacerbations of their disease. 
Effective treatment of sleep apnea improves symptoms of 
asthma. Various mechanisms have been proposed for the 
interaction between OSA and asthma. It has been hypoth-
esized that inflammatory mediators, secreted as a response 
to hypoxemia, cause bronchoconstriction. Nasal inflammation 
leads to increased levels of NO, IL-6 and 8-isoprostane, while 
systemic inflammation is associated with higher levels of reac-
tive oxygen radicals, ICAM–1, monocyte chemo-attractant 
protein 1 and IL-8.162
C H R o N i C  o B S T R U C T i v e  P U L M o N A R y  d i S e A S e 
( C o P d )
Patients with COPD may also have OSA. Approximately 
10% of patients with OSA have a coexisting pulmonary dis-
ease.163 A recent population study found that symptoms related 
to obstructive sleep apnea are common in subjects with asthma, 
bronchitis and rhinitis.164 Sanders et al165 concluded that, al-
though OSA and COPD are not clearly correlated, the degree 
of nocturnal hypoxia is greater in patients with both diseases. 
Weitzenblum166 supports the idea that the prevalence of OSA 
syndrome is not greater in COPD patients than in the general 
population, but this association is not rare since they are both 
frequent diseases. The mechanism of oxygen desaturation is 
different among OSA and COPD patients. While apnea is the 
most typical cause of oxygen desaturation in OSA patients, 
REM sleep-associated hypoventilation is the main reason for 
hypoxemia in COPD.
C o N C L U S i o N
The sleep apnea-hypopnea syndrome (SAHS) is a rather 
common problem in the general population. It implicates dif-
ferent pathophysiological mechanisms, such as increased sym-
pathetic activation, increased oxidative stress, inflammation, 
vascular endothelial dysfunction, increased platelet aggregabil-
ity, and metabolic disorders, all leading to enhanced risk for 
CVD and lower general health status. Not only cardiologists 
and pulmonologists but also physicians in the primary care 
practice should get familiar with the diagnosis and treatment 
of SAHS taking into account the fact that treatment with CPAP 
is associated with improvement of various clinical disorders, 
such as heart failure, hypertension, stroke, coronary artery 
disease and arrhythmias, and leads to a better clinical outcome. 
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